Intensivmedizin up2date, Table of Contents Intensivmedizin up2date 2013; 09(02): 113-127DOI: 10.1055/s-0032-1326626 Allgemeine Prinzipien der Intensivmedizin © Georg Thieme Verlag KG Stuttgart · New YorkNeue orale Antikoagulanzien (NOAK) in der Intensivmedizin Jürgen T. Lutz , Susanne AlbanRecommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Eisert WG, Hauel N, Stangier J et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885-1889 2 Büller HR, Prins MH, Lensin AW et al. EINSTEIN–PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297 3 Mega JL, Braunwald E, Wiviott S et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19 4 Oldgren J, Budaj A, Granger CB et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789 5 Alexander JH, Lopes RD, James S et al. APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708 6 Harder S. Renal Profiles of anticoagulants. J Clin Pharmacol 2011; 52: 964-975 7 Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. Clin Chem Lab Med 2011; 49: 755-757 8 Alban S. Monitoring von Antikoagulanzien. In: Barthels M, von Depka M, (Hrsg.) Gerinnungskompendium – Schnellorientierung, Befundinterpretation, klinische Konsequenzen. Stuttgart: Thieme; 2012: 764-795 9 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143 10 Samama MM, Amiral J, Guinet C et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-1079 11 van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127 12 Barrett YC, Wang J, Knabb R et al. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost 2010; 105: 181-189 13 Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-772 14 Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123: 1436-1450 15 Erenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579 16 Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of Dabigatran and Rivaroxaban: a randomised crossover ex-vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224 17 Levi M. Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012; 108: 201-202 18 Colwell CWJ, Kwong LM, Turpie AG et al. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21: 36-45 19 Gogarten W, Hoffmann K, van Aken H. Empfehlungen für die Anwendung konventioneller und neuer Antithrombotika aus anästhesiologischer Sicht. Unfallchirurg 2010; 113: 908-914 20 Schellong SM, Haas S. Perioperative Thromboseprophylaxe – Neue orale Antikoagulanzien und ihre Anwendung im Umfeld operativer Eingriffe. Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie 2012; 47: 266-273 21 Hilbert P, Teumer P, Stuttmann R. Prevention of thromboembolism in German intensive care units: Results of a nationwide survey. Anaesthesist 2008; 57: 242-250 22 Gogarten W, Vandermeulen E, van Aken H et al. Regional anesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesioogy. Eur J Anaesth 2010; 27: 999-1015 23 Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anesthesia for major orthopaedic surgery: management strategies. Anesthesia 2007; 62: 1154-1160 24 Loew A, Riess H. Perioperative Thromboseprophylaxe/Medikamentöse Thromboseprophylaxe in der Intensivmedizin. Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie 2012; 47: 254-262 25 Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 14: 1385-1413 26 Mueck W, Eriksson B, Borris L et al. Rivaroxaban for thromboprophylaxis in patients undergoing total hip replacement: comparison of pharmacokinetics and pharmacodynamics with once- and twice-daily dosing. Blood 2006; 108: 903
